New Polariser Installed at US Childrens Hospital Centre

Medical-imaging technology company Polarean Imaging, which offers a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, has delivered the latest version of its polariser to the centre for Pulmonary Imaging Research at the Cincinnati Children's Hospital Medical Center. The company holds a Small Business Innovation Research (“SBIR”) grant with the Cincinnati Children’s, which was awarded by the National Heart, Lung and Blood Institute (“NHLBI”) in April 2017.

As a non-profit academic medical centre, Cincinnati Children's is globally-renowned for paediatric teaching and research. It has been one of the Company’s key clinical collaborators following the award of the SBIR grant last year. A key focus of the collaboration is to lead the field of paediatric pulmonary imaging through advanced imaging techniques and multi-nuclear capabilities, including hyperpolarised Xenon-129.

Jason Woods, Director at the Pulmonary Imaging Research centre commented: “The combination of high polarisation provided by this machine and high throughput makes a significant difference for us in paediatric hyperpolarised-gas imaging, because we can generate multiple small batches, effectively on demand. This is particularly important when performing MRI on younger patients.”

Richard Hullihen, CEO of Polarean, said: “We are pleased to announce the delivery of the latest model of our xenon polariser in support of our SBIR grant with Cincinnati Children's and Dr Jason Woods' programme for advancing non-invasive hyperpolarized noble gas MR imaging in paediatric applications. We look forward to continuing our support of Cincinnati Children's breakthrough research efforts in early detection, therapy development, evaluation and management which we believe can improve the outcomes for these most vulnerable patients."